Ace Vision Group Names Ken Araki to Its Board of Directors
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named Ken Araki to its board of directors. Mr. Araki brings executive management experience and strategic leadership skills to support and drive commercial planning for the VisioLite® laser. The laser restores the eye’s natural dynamic range of focus through Laser Scleral Microporation (LSM), allowing patients to see clearly at all distances with the eye’s natural functionality. The VisioLite® Ophthalmic Laser System & LSM are not yet FDA approved or available in the United States. It is currently in clinical trials only in select areas outside of the United States.
Explore More Articles
Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
BOSTON, April 24, 2025 (GLOBE NEWSWIRE) — Ace Vision Group, Inc, (“AVG” or “the Company”) an emerging medical device company pioneering Laser Scleral Microporation (LSM) therapy for age-related vision loss, today announced the successful close of a $29.4 million Series B financing round.
read moreProfessor Marshall Continues to Propel Ace Vision Group Forward
Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named John Marshall, PhD, FRCPath, FMedSc as Scientific Advisor of Laser Technology. Professor Marshall is a pioneer of laser eye surgery, having developed computer-controlled excimer lasers for the correction of …
read moreVIDEO: Ace Vision Group provides update on presbyopia laser development
SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, AnnMarie Hipsley, DPT, PhD, and Alex Lopez of Ace Vision Group provide an update on the development of the VisioLite ophthalmic laser for presbyopia. The company is in a Series B2 round of funding.
read more